艾伯维于2026年2月24日宣布计划投资3.8亿美元在美国伊利诺伊州建设两座新活性药物成分生产设施， 以扩大神经科学和减肥药物的产能，并预计今年将公布更多投资计划。公司还于2026年2月21日任命Jag Dosanjh为高级副总裁兼免疫学业务总裁，强化管理团队。另据2026年2月20日公告，艾伯维将于2026年 4月15日除权除息，每股派息1.73美元。 股票近期走势 近7日（2026年2月20日至27日），艾伯维股价区间涨跌幅为0.99%，振幅达5.09%。截至2026年2月27日 最新数据，股价报226.56美元，当日涨0.83%，5日涨跌幅为0.78%；成交额较活跃，2月25日达12.35亿 美元。年初至今股价微跌0.05%，但过去52周累计上涨11.16%。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 近期艾伯维获多家机构关注，并宣布新的投资与人事任命。 机构观点 近期艾伯维获多家机构关注。2026年2月25日，RBC Capital首次覆盖艾伯维并给予"跑赢大盘"评级，目 标价260美元。此外，巴克莱银行于2026年2月20日首予艾伯维"买入"评级，目标价275美元。这些评级 反映了机构 ...

Core Viewpoint - AbbVie plans to invest $380 million to build two new active pharmaceutical ingredient production facilities in Illinois, USA, to expand its domestic production capacity for neuroscience and weight loss drugs [1] Group 1: Investment Details - The investment of $380 million will be directed towards the construction of new production facilities [1] - AbbVie already operates 11 production sites in the United States [1] - The company is in discussions with multiple states regarding potential projects and expects to announce further investments this year [1]

Core Viewpoint - 恒瑞医药 is a leading innovative pharmaceutical company in China, recently launched its IPO in Hong Kong, and is compared to other industry leaders like 宁德时代. The stock's pricing and foreign investment interest are under scrutiny, with a notable discount compared to its A-share price. Group 1: Company Overview - 恒瑞医药 has a market capitalization of 342.5 billion RMB and is recognized as a major player in the innovative drug sector [1] - The company has over 110 commercialized drugs, including 19 new molecular entity innovative drugs, and a pipeline of over 90 candidate new molecular entities [7] - In 2024, 52% of 恒瑞医药's revenue is expected to come from oncology drugs, with 15% from neuroscience [8] Group 2: Financial Performance - In 2024, 恒瑞医药's revenue is projected to reach 28 billion RMB, a year-on-year increase of 22.6%, with a net profit of 6.3 billion RMB, up 47% [9] - For Q1 2023, the company reported revenue of 7.2 billion RMB, a 20% increase year-on-year, and a net profit of 1.87 billion RMB, up 37% [11] - The revenue from innovative drugs increased from 38.1% in 2022 to 43.4% in 2023, and is expected to reach 46.3% in 2024 [13] Group 3: IPO Details - 恒瑞医药's IPO pricing range is set between 41.45 and 44.05 HKD, with a median price reflecting a 20.4% discount compared to its A-share price [3] - The subscription rate for the IPO is currently at 3.5 times, indicating moderate interest [5] - The company has engaged in 14 licensing transactions since 2018, generating approximately 14 billion USD in total transaction value, with 2.7 billion RMB expected from licensing in 2024 [15] Group 4: Market Position and Comparisons - Compared to 宁德时代, 恒瑞医药 has a lower foreign investment interest, with only 6% of its shares held by foreign investors as of Q1 2023 [1] - The discount on 恒瑞医药's IPO is higher than that of other innovative drug companies, such as 药明康德, which has a discount of only 4.2% [19] - The company’s P/E ratio is high at 50 times, and its P/S ratio is 11.7 times, indicating a premium valuation compared to peers [19]